| PHARMACEUTICAL TECHNOLOGIES |
PTRCR18
| | Dexamethasone for the treatment of COVID-19
Rapid Collaborative Review | 19.11.2020 | AIHTA | SNHTA | RER, MoH Ukraine | NA |
| PTJA16 |  | Venetoclax with a hypomethylating agent or low-dose cytarabine for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy | TBD | NOMA | JAZMP | AEMPS, NIPHNO, MoH Ukraine, SMCA | 02.04.2020 |
| PTRCR15 | | Remdesivir for the treatment of COVID-19
Rapid Collaborative Review: PICO and Evidence gaps | 29.09.2020 | INFARMED | NCPE | AIHTA, RER, MoH Ukraine | NA |
| PTJA14 | | Pretomanid as part of a combination regimen with bedaquiline and linezolid, in adults for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB) | 19.08.2020
Publication was delayed by 5 weeks due to EPAR unavailability | HAS | MIZ | MoH Ukraine, SNHTA, AEMPS, UU | 02.04.2020 |
| PTJA13 | | Satralizumab indicated for the treatment of adult and adolescent patients (≥12 yrs) with neuromyelitis optica spectrum disorders (NMOSD) | TBD | INFARMED | EUR, ZIN | AEMPS, JAZMP
Observer: VVKT | TBD |
| PTJA12 | | Glasdegib indicated for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) | 30.07.2020 | HVB | NCPE | INFARMED, SNHTA, HAS | 06.05.2020 |
| PTJA11 | | Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options | 16.06.2020 | NOMA | ZIN | AEMPS, HAS, IQWIG | 03.03.2020 (revised 17.04.2020) |
| PTJA10 | | Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and over | 21.10.2020 | ZIN | AEMPS | HAS, NICE, JAZMP | 28.07.2020 |
| PTJA09 | | Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD) | 12.03.2020 | FIMEA | AEMPS, AETSA | HAS, AOTMiT, HVB, RER Observer: HTA Department/EC Ukraine | 18.12.2019 |
| PTJA08 | | Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity | 13.02.2020 (revised 03.03.2020) | INFARMED | NCPE | AIFA, ZIN, SESCS/FUNCANIS,
RER | 20.11.2019 |
| PTJA07 | |
Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies
| 22.10.2019 | MIZ | TLV, AOTMiT | UCSC Gemelli, NIPN, SNHTA,
SESCS/FUNCANIS Observer: NCPHA | 29.07.2019 |
| PTJA06 | | Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant | 13.02.2020 | IQWIG | HAS | FIMEA, SUKL, TLV, INFARMED
Observer: GBA | 22.11.2019 (revised 12.02.2019) |
| PTJA05 | | Enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation | Product withdrawn from market authorisation | NOMA | AEMPS, AETSA | HAS, AIFA, SNHTA, HIS, DPA/MOH Malta | 11.02.2020 |
| PTJA04 | |
Sotagliflozin for adult patients with Type 1 Diabetes Mellitus who have inadequate blood glucose control using insulin or insulin analogues
Patient Input - Diabetes Type 1 | 07.06.2019 | TLV | ZIN, NCPE | AEMPS, SNHTA, NVD, INFARMED, AOTMiT
Observer: HIS, EOF
| 05.03.2019 |
PTJA03
| | Alecensa as monotherapy is indicated for the first-line treatment of adult patients with ALK+ advanced NSCLC | 23.01.2018 (revised 23.02.2018) | TLV | HVB, MIZ | NICE, Regione Veneto, AETSA, NIPN
Observer: MOH MALTA | 20.10.2018 |
| PTJA02 | | Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib treatment | 25.10.2017 | HAS | INFARMED | AAZ, SNHTA, FIMEA, LBI-HTA, NIPN, AETSA
Observer: EOF, EKAPTY | 21.07.2017 |
PTJA01
| | Midostaurin for the indication of Acute Myeloid Leukaemia | 08.11.2017 | FIMEA | NOMA | TLV, ZIN, HAS, NICE, AEMPS
Information retrieval: IQWIG
Observer: SUKL, EOPYY, SESCS | 28.06.2017 |
| OTHER TECHNOLOGIES |
| OTCA28 | | Lung cancer screening in risk groups | 04.12.2020 | IAMEV / AIHTA | IQWiG, AVALIA-T | UMIT, RER, Observer: UTA | 30.06.2020 |
| OTCA27 | | Comparative Effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia (BPH) | 31.03.2021 | RER | AIHTA | SNHTA, VASPVT, Regione Del Veneto | 31.07.2020 |
| OTCA26 | | Comparative effectiveness of surgical methods for treating people with morbid obesity | 02.04.2021 | NIPHNO | HIQA | VASPVT, AQuAS, HAS
| 11.08.2020 |
| OTCA25 | | Stereotactic Body Radiation Therapy (SBRT) for lung, prostate and hepatic cancer | TBD | AQuAS | AOTMiT | SNHTA, Regione Veneto, AETS-ISCIII
Project Manager: AVALIA-T | 01.07.2020 |
| OTCA24 | | A pulse wave analysis device (Mobil-O-Graph) and ARC solver algorithm to identify cardiovascular frailty | 01.07.2020 | HVB | UCSC/Gemelli | HIQA, AVALIA-T
Project Manager: MIZ | 03.12.2019 (revised 26.03.2020) |
| OTCA23 | | Biodegradable rectum spacers to reduce toxicity for prostate cancer | 28.07.2020 | NIPHNO | NSPHMPDB | NICE, SNHTA, VASPVT | 18.11.2019 (revised 24.04.2020) |
| OTCA22 | | Point-of-care Tests (POCT): D-Dimer and Troponin | 12.12.2019 | LBI-HTA | NSPHMPDB | SNHTA, HVB | 14.08.2019 |
| OTCA21 | | Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnoea | 18.06.2020
| AETS-ISCIII | NSPHMPDB | NIPHB, SFOPH/SNHTA, SESCS | 21.01.2020 (revised 21.05.2020) |
| OTCA20 | | Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR) | 18.11.2019 - 22.11.2019 | AETS-ISCIII | MoH Slovenia | UCSC Gemelli, SNHTA | 28.01.2019 |
| OTCA19 | | Screening for osteoporosis in the general population | 20.09.2019 | IQWiG | SNHTA | AQuAS, NSPHMPDB, GOG | 19.12.2018 |
| OTCA18 | | Regional hyperthermia for high-risk soft tissue sarcoma treatment | 31.10.2019 | NIPHNO | RER | VASPVT, AETS-ISCIII, SNHTA | 14.05.2019 |
| OTCA17 | | Lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH) | 22.11.2019 | AGENAS | RER | SNHTA, AETSA | 18.10.2018 |
| OTCA16 | | Bioresorbable Stents in cardiovascular indications (coronary artery disease) | 31.01.2019 | IAMEV/LBI-HTA | SNSMPS | SESCS, HAS | 20.08.2018 |
| OTCA15 | | Irreversible electroporation in liver and pancreatic cancer | 05.07.2019 | AVALIA-T | LBI-HTA | VASPVT, NIPN, SNHTA | 23.10.2018 |
| OTCA14 | | Robot-assisted surgery in thoracic and visceral indications | 06.05.2019 | LBI-HTA | Regione Veneto | HIQA, DEFACTUM | 11.07.2018 |
| OTCA13 | | Vagal nerve blockade for obesity | Cancelled: expiration of CE approval for the technology | NIPHNO | VASPVT | SESCS/FUNCANIS, NIPHB | Cancelled: expiration of CE approval for the technology |
| OTCA12 | | C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs) | 29.01.2019 | HIQA | HVB | UCSC Gemelli, AETSA, AGENAS, HIS
Observer: AOTMiT | 19.04.2018 |
| OTCA11 | | Custom-made or customisable 3D printed implants and cutting guides versus non-3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery | 19.04.2019 | DEFACTUM | OSTEBA | GÖG, KCE, MIZ, NIPN | 16.11.2018 |
| OTJA10 | | Stool DNA testing for early detection of colorectal cancer | 26.07.2019 | GÖG | NIJZ, JAZMP | NICE, AGENAS, DEFACTUM, OSTEBA
Observer: MoH Slovenia | 25.07.2018 |
| OTCA09 | | High-intensity focused ultrasound (HIFU) ablation for the treatment of prostate cancer | 12.04.2018 | LBI-HTA | VASPVT | SNHTA, AETS-ISCIII, OSTEBA | 26.02.2018 |
OTJA08
| | Continuous glucose monitoring (CGM real-time) and flash glucose monitoring (FGM) as personal, standalone systems in patients with diabetes mellitus treated with insulin | 27.07.2018 | MIZ | HVB, NIPHNO | AQuAS, HIS, RER
Observer: ACSS-IP, AOTMiT | 28.02.2018 |
| OTCA07 | | Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard ultrasound phacoemulsification cataract surgery | 26.10.2018 | RER | GOG | KCE, Osteba, SESCS/FUNCANIS and AQuAS
Observer: VASPVT | 15.02.2018 |
| OTCA06 | | Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgical risk | 21.12.2018 | AGENAS | NIPHNO | SNHTA, OCSC, HIQA, KCE, Regione Veneto | 08.11.2017 (revised 20.12.2017) |
| OTCA05 | | Repetitive transcranial magnetic stimulation for treatment-resistant major depression | 21.04.2017 | LBI-HTA | Osteba | KCE, FUNCANIS | 21.04.2017 |
OTCA04
| | Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer | 03.01.2018 (revised 06.02.2018) | ZIN | KCE | LBI-HTA, HAS | 10.11.2017 |
| OTCA03 | | Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT) | 09.02.2018 | Avalia-t | RER | MIDT, SNHTA, NIPN, IQWIG
Observer: EOPYY | 22.03.2017 |
| OTCA02 | | Antibacterial-coated sutures versus non-antibacterial-coated sutures for the prevention of abdominal, superficial and deep, surgical site infection (SSI) | 27.04.2017 | MIZ | NSPHMPDB | SUKL, NIPN/OGYEI, VASPVT, SNHTA, IQWIG | 06.10.2016 |
| OTCA01 | | Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk | 20.12.2016 | LBI-HTA | MIZ | Avalia-t, IQWiG | 09.09.2016 |
= Patients have been involved in the assessment.
All EUnetHTA JA3 Assessment reports are published under the Creative Commons license CC-BY-NC.